



GP-TCM RA Elections - President-Elect and Members of Board of Directors (2021-2022)

With the approval of the current GP-TCM RA Board of Directors (BoD), the Secretariat is holding the 5th GP-TCM RA election for **nine** BoD members, **including** President-Elect.

Standing for President-Elect

Professor Clara Bik-San LAU BPharm, PhD, MRPharmS



Self-introduction

Professor Clara Lau is currently the Associate Director of the Institute of Chinese Medicine and the State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants at The Chinese University of Hong Kong. She also has a courtesy appointment as Associate Professor at the School of Chinese Medicine, CUHK. With BPharm and PhD in Pharmacy (Pharmacognosy) from King's College London, University of London, UK, she has a continuous interest in both western herbals and traditional Chinese medicines (TCM), and has over 26 years' experience in Pharmacognosy and herbal/natural products research, focusing on anti-cancer natural products and beneficial herb-drug interaction. She has published over 250 SCI journal articles and 8 book chapters, and has successfully supervised/co-supervised 12 postdoctoral fellows and 35 MPhil/PhD postgraduates in Chinese Medicine, Pharmacognosy or Biochemistry. Currently, she serves as member of ChP-USP Advisory Group on Monographs for TCM Ingredients and Products; Acting Secretary-General of The Consortium for Globalization of Chinese Medicine (CGCM); Secretary-General of Good Practice in Traditional Chinese Medicine Research Association (GP-TCM RA); Council member and Associate Chief Executive of Modernized Chinese Medicine International Association (MCMIA); Associate Editor of "*Journal of Traditional and Complementary Medicine (eJTCM)*", Consulting Editor of "*Pharmacological Research*", and Editorial Board member of journals "*Phytomedicine*", "*Scientific Reports*", "*Journal of Natural Products*", "*Journal of Ethnopharmacology*" and "*Journal of Pharmacy and Pharmacology*".

Personal statement: Why do you apply for the position? What will you do if elected?

Being an active member of GP-TCM RA, I had attended the 2nd to 7th Annual meetings, during which I had been awarded with best poster prizes, and as invited/keynote speakers in the recent annual meetings. Since 2017, I began to serve as the Secretary-General and had the opportunity to contribute more towards the Association, such as the administrative work, and being the organizing and scientific committee members of the 7th Annual meeting in South Korea, and the coming 8th Annual meeting in Lithuania. With these experiences, I am very honoured to be nominated by Past President Tai-Ping Fan and current President Aiping Lu to go for the election of President-Elect. If I got elected, I would like to contribute as follows:

- a) With strong administrative and organizational skills, plus language fluency in English, Cantonese and Putonghua, together with extensive global research networks in TCM/natural products field, also currently serving as council members/executive committee members of various international TCM related organizations (e.g. CGCM and MCMIA), I am certain that I can help to promote interdisciplinary and interregional research collaborations and network among members of GP-TCM RA and these organizations. I would also like to help recruiting more members and increasing the networking from those countries in the Belt and Road region.
- b) I am in full support of GP-TCM RA's objective in promoting high-quality evidence-based TCM research through developing, disseminating and implementing good practice. Apart from the continuation of my active academic role in coaching young TCM researchers (mainly in the fields of pharmacological research and quality control), I am eager to work with the 7 Interest Groups' chairpersons in order to foster implementation and further development.
- c) I am also dedicated to continue my service as the Secretary-General and will work closely with the new President and Treasurer to ensure the smooth running of the daily operation. Within the coming two years, I will actively search for an appropriate member to prepare to take up the Secretary-General role in 2023.

With the support of BoD and all members, I look forward to the continuous development and increasing global influence of our Association in the TCM field in the coming years.

Standing for positions on the Board of GP-TCM RA

The following candidates are listed according to the alphabetical order of their surnames.

1. Professor Rudolf Bauer



Self-introduction

Studied pharmacy at University of Munich; Ph.D. in 1984; 1993-2002 associate professor at the Institute of Pharmaceutical Biology, University of Düsseldorf; since 2002 professor of pharmacognosy at University of Graz, Austria; 2004 – 2020 Head of Institute of Pharmaceutical Sciences at University of Graz, now Deputy Head; since 2008 head of TCM Research Center Graz – medicinal plant research. Guest professor at School of Chinese Materia Medica, Beijing University of Chinese Medicine; Guangxi Botanical Garden of Medicinal Plants and Institute of Guangxi Medicinal Plants, Nanning; Institute of Medicinal Plant Development, China Academy of Medical Sciences, Beijing; Chengdu University of TCM; Heilongjiang University of CM, Harbin; Changchun University of CM. Recipient of Egon-Stahl-Award of the Society for Medicinal Plant Research (GA); Norman Farnsworth Excellence in Botanical Research Award; Qihuang International Prize of China Association of Chinese Medicine, Outstanding International Scientist Award (Pranab Banerji Memorial Award) of the Society for Ethnopharmacology India (SFE). Honorary doctorate of University of Helsinki.

Associate Editor in Chief of Chinese Journal of Natural Medicines and World Journal of Traditional Chinese Medicine (WJTCM). Chairman of the expert group on Chinese herbs of the European Pharmacopoeia. Previous president of the Society for Medicinal Plant and Natural Products Research (GA) and of the International Society for Ethnopharmacology (ISE). Long experience in natural product chemistry; ca. 390 scientific publications.

Personal statement: Why do you apply for the position? What will you do if elected?

I have been committed to best practice in TCM research since almost 30 years, and have always supported the GP-TCM project. I have served for two years as the founding president of GP-TCM Research Association and another two years as the past president in the ExC of GP-TCM RA. During this time, I have been organizing the 2nd annual meeting of GP-

TCM RA in Graz in 2013. I have been an active member of the GP-TCM RA Board in the previous period and want to continue serving our Association mainly in the fields of pharmacological research, quality control, and regulatory affairs. I also would like to act as a link of GP-TCM RA to other organizations, like GA, ISE, and the Consortium for the Globalization of Chinese Medicine, in order to establish a powerful network. A further goal is to stimulate international research collaborations in the field of TCM and to tighten the bonds between Europe and China.

2. Mr. Abraham Yu Ling Chan



Self-introduction

I am the founder and Chairman of PuraPharm Corporation Ltd, a publicly traded company listed on the Main Board of HK Stock Exchange. PuraPharm dedicates itself to the modernization and internationalization of traditional Chinese medicine (TCM) and is a leading company engaged in the R&D, production, marketing and selling of concentrated Chinese Medicine granules (CCMG) products. PuraPharm has been supplying CCMG to the majority of hospitals in Hong Kong since 2004 and is one of the only five, and the only non-PRC company licensed by the CFDA to manufacture and sell CCMG products in China. PuraPharm is the largest and the leading CCMG manufacturer in Hong Kong, and owns the largest Chinese medicine clinic chain in HK.

PuraPharm's own TCM research & production facilities is based in Guangxi, China which complies with the PRC Good Manufacturing Practice (GMP) standards, as well as Australia's Therapeutic Goods Administration (TGA) standards. PuraPharm also owns a Chinese herbs plantation site in the province of Guizhou, China, covering an area of over 4,000 acres.

As the founder and the Chairman of the Company and with extensive experience in Chinese medicine and healthcare products, I am responsible for directing the overall strategies and planning of the Group's business. I also lead the Group's R&D and technological development functions. PuraPharm, actively collaborating with various universities and research institutes internationally, has established itself as the technological front-runner within the industry. Through continuous innovation, PuraPharm has come to be regarded



as a leading company in the research and development of traditional Chinese medicine.

I hold positions in various organizations:

<u>Organizations and associations</u>	<u>Position</u>
The Chinese Medicine Hospital Project Office (CMHPO)	Member
Government Chinese Medicines Testing Institute (GCMTI) Advisory Committee	Member
Hong Kong Baptist University Pharmacy in Chinese medicine Programmes Advisory Committee	Advisory committee member
School of Pharmacy of The Chinese University of Hong Kong Advisory Committee	Advisory committee member
Bachelor of Pharmacy Programme of the Department of Pharmacology and Pharmacy, Faculty of Medicine, the University of Hong Kong	Advisory board member
School of Chinese Medicine Advisory Committee (SCMAC)	Ex-Chairman and currently Member
Modernised Chinese Medicine International Association Ltd.	Founding council member
The International Society of Oriental Medicine, Korea	Board member (Hong Kong representative)
The Association of Hong Kong and Kowloon Practitioners of Chinese Medicine Limited	Advisor
The Hong Kong T. C. M. Orthopaedic and Traumatic Association Ltd.	Advisor
Chinese Medicine Development Committee of HKSAR	Previous Member
Hong Kong Advisory Council on Food and Environmental, HKSAR	Previous Member

Personal statement: Why do you apply for the position? What will you do if elected?

With my extensive industry experience in the commercial sector, I will strive to help foster the development of Chinese medicine in Europe. I have been leading PuraPharm's R&D functions and we have a strong scientific advisory committee. We have worked with world-renowned scientists advising us on the prevailing research trends and the updated technologies for our product development. Further, I am committed that with my connections with both local and internationally renowned academics, the development of Chinese medicine can be advanced to a platform beyond the stage of basic sciences and clinical research. Further exchange and advancement of Chinese medicine between HK and Europe will be cultivated, and outcomes from Chinese medicine research can result in practical application and be transformed to final products available to the community and benefitting the humankind. I have extensive experience in transforming the results of different stages of Chinese medicine research to commercial products.

I am also fully committed to the establishment of quality standards for CCMG products through PuraPharm's continuous cooperation with the China's Food & Drug Administration (CFDA), the Committee for the Chinese Pharmacopoeia and major universities in Hong Kong, the PRC and overseas countries. Our laboratory is certified by the China National Accreditation Service for Conformity Assessment (CNAS), the international multilateral recognition system equivalent to an accreditation in accordance with the ISO 17025 standards, and PuraPharm is the first CFDA-licensed CCMG product manufacturer qualified with such a laboratory that can issue safety reports recognized by over 70 countries around the world. PuraPharm is also the only CFDA-licensed CCMG product manufacturer having received the United States Pharmacopeia (USP) verification of its CCMG products according to the U.S. Pharmacopeial Convention. We currently collaborate with the USP in the standardization of CCMG products. These are what we can offer to the association to advocate high-quality evidence-based research and development of TCM.

My visions and commitment above coincides with the missions of Good Practice in Traditional Chinese Medicine (GP-TCM) Research Association to promote high-quality evidence-based research of TCM through developing, disseminating and implementing good practice. I will continue to foster exchange and cultivate advancement, to pioneer the modernization and internationalization of TCM, and to offer professional, quality, effective, safe and reliable products through the oriental wisdom of TCM if I got elected as a Board Director of GP-TCM RA.

3. Professor Pierre Duez



Self-introduction

PhD in Pharmaceutical Sciences (Toxicology), Pierre Duez heads a teaching and research department in the Université de Mons (Faculty of Medicine and Pharmacy); he is teaching Pharmacognosy, Pharmacology, Nutrition and bibliographical tools, both in theory and practice. He has access to chromatographic and spectroscopic techniques for Belgian and foreign PhD students. Specialized in the study and analysis of natural products, the team concentrates on the elucidation of DNA repair modulators and on the integration of traditional medicines with African modern medicine (DR Congo). Pierre Duez is member of the

European Pharmacopoeia TCM working party, of the European Medicines Agency (Monograph and List Working Party), of the Belgian Commissions of Pharmacopoeia and Registration of Herbal Medicines. He is active in development cooperation with Algeria, Argentina, Burkina Faso, Ecuador, Uganda, DR Congo, PR China (Macao), Rwanda, Madagascar, Vietnam. Member of the GP-TCM consortium, he is currently Board Member and Chair of the Pharmacology & Toxicology Interest Group for the GP-TCM RA. He is (co-)supervisor of 21 defended theses, co-editor of 1 book, co-author of 10 book chapters, 169 scientific papers, 1 report for the European Development Fund, 1 patent and 328 communications in meetings. He has organized the 2015 GP-TCM RA meeting in Mons, Belgium.

Personal statement: Why do you apply for the position? What will you do if elected?

My interest in TCM dates back to 1992 with the affair of "Chinese herbs nephropathies" in which I was closely associated for elucidating the adulteration responsible for intoxications. The GP-TCM consortium has allowed me to delve much deeper in the various problems associated with TCM documentation, quality and toxicology, while meeting leading experts in the field. As GP-TCM RA Board Member, I have tried to contribute to maintain the group and to further advance its unique possibilities. As Chair of the Pharmacology & Toxicology Interest Group, I have summarized the challenges associated with herbal medicines and established a plan for action (<http://www.gp-tcm.org/work-packages/wp3-functional-genomics-in-toxicology-study-of-chinese-herbal-medicines/>). In my current position of vice-rector for mobility and international relations in my university, I intend to further develop relationships with research and teaching teams, particularly in Asian countries.

Besides further contributing to developing the Association, one of my major interests resides in joining the forces of the Pharmacology & Toxicology Interest Group members to begin developing concerted actions, with concern in relating quality and regulatory aspects. These are key issues for acceptance of TCMs in Europe. I do not forget that medicinal herbs are used throughout the world, either as complementary and alternative medicines or as primary cares resources. The latter is particularly the case in Sub-Saharan Africa where 80% of people rely on traditional medicine for healthcare. Introduction of young scientists from all over the world to the advances of TCM will help in improving the current standards of care in developing countries by implementing local strategies for herbs quality control and safety assessment. We currently develop such a strategy in DR Congo through the project PhytoKat, funded by Belgian cooperation.

In this age of Covid, I intend to develop a working group that will investigate the rationale behind the multiple clinical trials undertaken with TCM products in the fight against coronavirus infection.

4. Professor Thomas Efferth



Self-introduction

Professor Dr. Prof. h. c. mult. Thomas Efferth is chair of the Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Mainz, Germany. He is biologist by training (Technical University of Darmstadt, Germany). Doctoral thesis: German Cancer Research Center (DKFZ), Heidelberg, Germany (1990). Awards: Prize of the Southwest German Association for Medicine (1991), Willmar-Schwabe-Award of the German Society for Medicinal Plant Research (2006), citizen medal of the City of Heidelberg, Germany (2008), CESAR Award for Translational Oncology (2011), SCENTEdrop Award on medicinal and fragrant herbs (2015), *Qihuang* International Award of the Chinese Association of Chinese Medicine (2017). Since 2018, he is full member of the World Academy of Sciences.

He headed a research group for Pharmaceutical Biology at DKFZ (2005-2009) and was adjunct professor (apl.) at the University of Heidelberg (2007-2009). In 2009, he took over the Chair of Pharmaceutical Biology (full professorship) at the Johannes Gutenberg University, Mainz. Furthermore, he is honorary professor at the Northeast Forestry University, Harbin, and at the Zhejiang Chinese Medical University, Hangzhou, China. Moreover, he is visiting professor at the Zhejiang University of Science and Technology, Hangzhou, China and honorary adjunct professor at the Chinese University Hong Kong.

Thomas Efferth published 650 PubMed-listed papers and in peer-reviewed journals in the field of cancer research, pharmacology, and natural products (Hirsch-factor: 82; citation rate: 30,000; acc. Google Scholar) and a textbook on 'Molecular Pharmacology and Toxicology' (Springer Publisher; 2006). He holds 7 patents. The scientific results were communicated in over 270 oral presentation and invited lectures and over 200 poster presentations at national and international conferences and meetings. He is editor-in-chief of *Phytomedicine* and *Phytomedicine Plus* as well as associate editor of several other scientific journals and scientific advisory board member (e.g. German Pharmaceutical Society, Hong Kong Research Grant council etc.). Thirteen of his former lab members promoted to leading academic positions (1 president, 2 full professors, 10 associate/assistant professors).

The focus of Dr. Efferth's research is on tumor pharmacology, network pharmacology, and recently also on COVID-19. A major topic is research on chemical entities from natural

sources:

1. Systems biology and bioinformatical approaches to unravel modes of actions of synthetic and natural compounds with activity against otherwise drug-resistant tumors and infectious agents (basic research)
2. Predictive and prognostic markers for personalized medicine (translational research)

For more details see: <http://www.pharmazie.uni-mainz.de/Ak-Efferth/index.php>

Personal statement: Why do you apply for the position? What will you do if elected?

My personal motivation to apply as member of the Board of Directors is mainly due to the fact that I have been working in the field of natural products with a focus on Chinese herbs for more than 20 years. I strongly felt that Chinese medicine and in a broader sense Traditional Medicine in general needs to be further promoted in the scientific world. The therapeutic potential of traditional medicines needs to be systematically explored for the sake of millions of patients worldwide. To reach this goal, scientific platforms are needed for collaboration and scientific exchange. GP-TMR provides an exquisite opportunity for such a platform. For this reason, I like to contribute to realize the major goals of GP-TMR. From a personal point of view, I estimate the following topics of special relevance:

1. Strengthening interdisciplinary approaches between basic research and medical application.
2. Integration of traditional medicines into academic school medicine. To realize this goal the rules of evidence-based medicine should be applied to traditional medicines.
3. My personal research focus is on cancer, the elucidation of molecular modes of action, pharmacogenomics and strategies for therapeutic intervention of cancer by phytotherapy and phytochemicals derived thereof.
4. Fostering careers of young researchers in traditional medicine.

5. Dr Tai-Ping Fan



Self-introduction

Trained in immunopharmacology, Dr Tai-Ping Fan has worked at Cambridge University for more than 30 years aiming to develop safe, effective and affordable phyto-pharmaceuticals

from TCM and other ethnic medicines.

With his collaborators in Xi'an, Wuxi and Jinan, they have developed *Jun-Shi Medicinal Compatibility Model* for discovering and patenting pro-angiogenic, anti-convulsant and anti-hypertensive compounds, and elucidating their molecular mechanisms of action. Recently, they have developed engineered *E. coli* and cell-free biosynthetic approaches to generate natural products of therapeutic value; established a comprehensive zebrafish-based platform for evaluation of bio-activities and toxicity of natural and synthetic chemicals.

In 2017, he was instrumental in convincing the Czech Chamber of Deputies to incorporate TCM into the Czech healthcare system. In response to the COVID-19 outbreak, Dr Fan has collaborated with a Chinese biotech company and used its patented Plant Low-temperature Extraction & Efficient Separation Integration Technology to eliminate heavy metals and pesticide residues and to produce high-quality herbal granules from established TCM formulations for the prevention and treatment of coronavirus infection.

In addition to prestigious professorships in universities and research associateships in research institutes, Dr Fan was honoured with the 2019 Qihuang International Prize from China Association of Chinese Medicine.

- Publications <https://scholar.google.co.uk/citations?user=NzK2TBcAAAAJ&hl=en>
- Outreach <http://www.phar.cam.ac.uk/research/fan/outreach>

Personal statement: Why do you apply for the position? What will you do if elected?

Invited by Dr Qihe Xu of King's College London in 2009, I became a Deputy Coordinator of the GP-TCM Project, focusing on Regulatory framework in R&D of Chinese herbal medicines. Since the founding of the GP-TCM RA in April 2012, I have served as its Secretary-General (2012-2014), President-elect (2015-2016), President (2017-2018) and Past President (2019-2020). Following the premature death of Professor Peter Hylands in June 2019, the BoD appointed me as Treasurer. Despite initial difficulties, we have re-activated our bank account to serve our members more efficiently. With wide-ranging experiences, I am keen to join the BoD for 2021-2022.

If elected, I would like to continue to serve as Treasurer, working closely with President Monique Simmonds and Secretary-General Clara Lau. Furthermore, I will actively support all BoD members, Newsletter Editors, Chair/Co-chair of Interest Groups. I will reach out to young academics globally and mentor them for future responsibilities, recruiting more Corporate and Institutional Members. In August 2020, I was invited by China Food & Drug Safety Blockchain Special Committee to assemble an international consortium with experts from 22 countries and Greater China. As this consortium's first chairman, I intend to invite new blood to join our Association, further strengthening academic-industry collaboration.

6. Professor Rong-Rong He



Self-introduction

Professor Rong-Rong He is the Director of Guangdong Engineering Research Center of Chinese Medicine & Disease Susceptibility in Jinan University, Guangzhou, China. She also serves as the Vice Dean of TCM College and Associate Director in the Institute of Traditional Chinese Medicine and Natural Products, College of Pharmacy, Jinan University. She gained her Pharm and PhD in Pharmacy (Chinese Materia Medica) from Shenyang Pharmaceutical University, Shenyang, China. The effectiveness of herbal medicine has always been difficult to evaluate with conventional pharmacological methods. To tackle these problems, she focuses on using a variety of stress-loaded models for anti-stress research and natural product evaluations and improving their effectiveness on homeostasis and disease prevention. This series of novel research projects are supported by dozens of funding sources such as National Natural Science Foundation. As a young researcher, she has published over 100 scientific articles in peer reviewed journals, presented scientific reports in local, national and international conferences, and is the owner of 6 authorized patents. In 2019, Dr. He has been awarded with the Guangdong Provincial Science and Technology Progress Award (First Class) and Technological Progress Award from Ministry of Education (Second Class) for her original contributions for the TCM studies.

Personal statement: Why do you apply for the position? What will you do if elected?

Recommended by Drs De-An Guo and Tai-Ping Fan, and Invited by President Aiping Lu and Secretary-General Clara Lau in 2019, I became a GP-TCM RA BoD member for a 2-year term (January 2019 - December 2020). During this period, I have made much progress in academic field of TCM research. My role of BoD members was mainly to attend the monthly BoD Skype meetings. Although I did not express my views on GP-TCM RA issues very often, I did learn a lot from it. As a young BoD member in China, I would like to learn from senior members and gain experiences in global policies and international collaboration, and to actively serve the GP-TCM RA in the future. With wide-ranging TCM research experiences and developing potential, I am very keen to join the BoD for 2021-2022.

If elected, I would like to continue to serve as BoD member, working closely with President Monique Simmonds and Secretary-General Clara Lau. Furthermore, I will actively support

all BoD members, Newsletter Editors, Chair/Co-chair of Interest Groups. I will attend the monthly BoD skype meeting and to express my views on GP-TCM RA issues. I will also attend and help to organize the Annual meetings.

7. Professor Nicola Robinson



Self-introduction

Nicola Robinson is Emeritus Professor of Traditional Chinese Medicine and Integrated Health, London South Bank University, UK. Having obtained a PhD in immunology at Manchester University she became a registered acupuncturist in 1982 and awarded Fellowship of the British Acupuncture Council (BAcC) in 2008. In 2004, Nicola was awarded a Winston Churchill Traveling Fellowship to visit China, for 8 weeks, exploring educational and research initiatives in TCM and began her collaboration with Chinese academics. As well as TCM, she also has considerable research experience in public health and health services research. She is Editor in Chief of the European Journal of Integrative Medicine (Elsevier) and on the board of 5 Chinese academic journals. Nicola has written over 200 scientific articles in peer reviewed journals and presented internationally. She has successfully supervised Chinese and UK PhD and postdoctoral students. Her research has included many topics using different methodologies with the aim of highlighting the importance of integrated medicine including; stroke, muscular skeletal pain, phantom limb pain, osteoarthritis of the knee, post marketing surveillance of herbal injections and clinical guidelines. In 2018, she was honoured to be awarded the role of visiting overseas master professor role by the Ministry of Education of the People's Republic of China at the Centre for Evidence Based Chinese Medicine at Beijing University of Chinese Medicine.

Personal statement: Why do you apply for the position? What will you do if elected?

I have been active in GPTCMRA since its inception as one of the founding board members and previously Secretary General. I would like to offer my experience and past knowledge to serve again as a board member. I was a co-ordinator for 2 work packages for the original GPTCM project. I chair the GPTCM RA Acupuncture Interest Group (AIG) and co-host at the successful GPTCM RA meeting held at Kew and LSBU in 2018. My wish is to ensure

that multidisciplinary research collaborations can flourish facilitating learning between different countries. I also feel passionate about the need to build capacity by developing young researchers having previously contributed to young researchers' workshops. Through my editorial work, I have developed knowledge on the ever increasing network of researchers in the area of Chinese Medicine whose energies can be harnessed. I am involved in a range of research projects spanning different countries and cultures and continue to expand my links with China.

As a previous Chair of the Research Council for Complementary Medicine, UK, and Chair of the Research Committee of the BAoC I have worked closely with professional groups and interested practitioners to stimulate research. I sit on the UK advisory board for the Medicines Control Agency. It would be my great pleasure to continue to serve GPTCM RA again and provide local support to the new President Elect, Prof Monique Simmonds.

8. Professor Helen Sheridan B. Sc, PhD, MA, FTCD, FRSC.



Self-introduction

I am a founding and life member of the GP-TCM; Academic Director and Founder, of NatPro the TCD Centre for Natural Product Research (2019) at Trinity College Dublin (TCD); former Director of Research at the School of Pharmacy (2016-19). I was elected to fellowship at TCD (FTCD; 2020); awarded the Provost's Teaching Award (2019); Elected to Fellowship of the Royal Society of Chemistry (2016). I Founded Trino Therapeutics Ltd – A TCD Spin-out (2000) in drug discovery. My research is the area of natural product inspired drug discovery. I have brought one molecule to Phase 1 human trials through the MHRA. I have secured €19,697,672 research funding: from National, international, Venture and Philanthropic funding, including a prestigious Wellcome Trust Translation Award (€3M co-PI). I was recently awarded €6M in Philanthropic funding from the Department of Justice/ IIP programme from Chinese Investors "Kylin Prime Group", for a Natural Product project looking for commercial or therapeutic discoveries from the bogs of Ireland. I am the phytochemical expert to the National Health Products Regulatory Authority (HPRA) (2000-to date). I have 89 peer reviewed publications including 7 international patents in drug discovery. I worked Part time >25 years due to a chronic medical condition.

Personal statement: Why do you apply for the position? What will you do if elected?

I received a gift, a book on China in 1983 while working in the University of Oxford. That book inspired me. When I was invited by Dr Qihe Xu, in 2009, to join the GP-TCM consortium application to EU-FP7, I had no hesitation, finally, China was calling.

I am an Irish academic and researcher, from Trinity College Dublin (TCD). I work to ensure the 'WHO' aspiration to integrate traditional and allopathic medicine becomes a global reality. I am the Herbal Medicines Expert on the Irish *Health Products Regulatory Authority* (2000-to date). I have presented on quality and modernisation of TCM to the European Medicines Agency (EMA). The GP-TCM society has been a wonderful opportunity to embrace the field of TCM, and to contribute my unique experience. If elected as a Board member, I will work with President Simmonds and Secretary-General Lau, and the Board, to further the aims and to contribute to new visions for GP-TCM. I will continue to engage with my GP-TCM colleagues, on scholarship, research, regulation and dissemination of TCM. Our research centre NatPro will link GP-TCM with its national and international academics, scholars and fellows and industrial networks to support research in TCM.

9. Dr. Mei Wang



Self-introduction

Dr. Mei Wang, founder and chairperson of LU-European Center for Chinese Medicine and Natural compounds (LUECCM), Institute of Biology, Leiden University,, Netherlands, expert member and representative of Dutch pharmacopeia for TCM working party at European pharmacopeia committee EDQM, vice-chair of the World Federation of Chinese Medicine (WFCMS) Specialty Committee of innovative natural medicine, board member of NVF (Dutch association of Phytotherapy, member of ESCOP), associate editor of the journal *Phytomedicine*.

She holds a PhD (1988) in cell biology and genetics from Leiden University, Netherlands and a BSc (1982) from Peking University, P.R. China. Based on a huge science and business success in the field of secondary plant metabolites in animal (and human) systems, she formed a Plant Systems Biology group linked with TNO Systems Biology Technology

platform and Leiden University Pharmacognosy Research group. From this activity onwards the innovative strategy on bridging Western and Eastern medicine based on TCM and the company SUBiomedicine was established in 2004. She is the CEO of SUBiomedicine. SUBiomedicine has realized, as the first company in the world, the registration of a Chinese medicine product according to tHMP (traditional Herbal medicinal product) rules in Europe that is produced in China. In 2018, she obtained the international “Qihuang prize” which was awarded by Chinese Medicine Society.

Personal statement: Why do you apply for the position? What will you do if elected?

I would like to apply for the position of BoD member of GP-TCM because I believe the mission of GP-TCM and want to support realizing the objectives of GP-TCM from European perspective.

In the past years, I was proactively involved in the interactive network established by the FP7 GP-TCM consortiums and nurtured international young students and researchers to better understand TCM principles and research at different levels in an interdisciplinary approach. These activities include supervising MSc and PhD students (have supervised 15 PhD students and currently is supervising 3 PhD students) and creating MSc courses on “Pharmaceuticals from Plants” at Leiden University. In particular, I would like to contribute on international collaborations and sharing of resources, expertise and good practice among academia, industry and regulatory agencies.

If elected, I will continue to promote high-quality evidence-based research of TCM and support the growth of GP-TCM via facilitating the work of Interest Groups (I am also the chairperson of Interest Group regulatory affair) and potential collaborations, particularly between Europe and China. My goal is to strengthen interdisciplinary collaborations in TCM research and development, to promote scientific research outcomes and latest developments in regulatory sciences to stakeholders, industry, professional groups and the public, ultimately to enhance the global impact of GP-TCM.

10. Professor Vivian Taam Wong JP MBBS, FRCOG, FFPH, FRCP (London), FHKAM
Hon Fellow of HKU and OUHK



Self-introduction

- Hon Professor, School of Chinese Medicine, HKU
- Hon President, Hong Kong Association of Chinese-western Medicine
- Vice President, Modernized Chinese Medicine International Association
- HK Coordinator, Consortium for Globalization of Chinese Medicine
- Council Member, Chinese Association of Integrative Medicine
- Member, International Chinese Medicine Clinical Standards Working Committee, WFCMS

Key Past Appointments:

- Public Health Specialist, Policy & Research, World Bank
- Chairman, Committee on Safe Motherhood, International Federation of Gynecology & Obstetrics
- Consultant on various Committees under WHO
- Consultant on Health Project IV & VI in China for World Bank
- Chief Executive, Queen Mary Hospital & Hospital Authority, HK
- Hon Advisor in Integrative Medicine, Hospital Authority, HK
- Hon Senior Advisor on Chinese Medicine, Medical Faculty, HKU

She has been on editorial boards of 7 journals, and published >130 peer-reviewed papers. She set up the unique HK-wide Research Ethics Committee system & standards enabling multicentre trials as well as the high quality network of Chinese Medicine Centres for Training and Research in each district in HK. While steering education, research and knowledge transfer in integrative medicine, she has fostered collaboration among the Government, industry, Universities and researchers to plan a “Greater Bay Area CM Innovation and Trading Park”.

Personal statement: Why do you apply for the position? What will you do if elected?

As an advisor to the EU FP7 program “GP-TCM in the Post Genomic Era”, I learnt, via the Working Packages, from many scientists deeply committed to the study of ethnopharmacology in general and Chinese medicine in particular.

I conducted the first Randomized Controlled Trial in the use of Acupuncture for induction of labour in HKU in the 1970s. Over the past 40 years I have been engaging both western and Chinese scientists in research to support “Evidence-based Medicine” (EBM).

As a Director of GP-TCM RA from her inauguration, I contributed to the expansion of networks, with a view to help steer the development of Good Practices along the whole supply chain from GAP to GCP. Endowed with world renowned Medical Faculties in HKU and CUHK, our experience and expertise in Phase 1, 2 & 3 trials, will facilitate human studies for the international market.

With the “Greater Bay Area CM Innovation and Trading Park”, to be located in the Pearl River delta, HK will play an important role in harmonizing international standards in herbal quality and clinical practice. In 2019, I started the “Good Clinical Practice Guideline” (GCPG) Interest Group. We need to attract more integrative medicine clinicians to recognize the scientific rigor, appreciate the EBM and accept our GCPGs.

11. Dr. Qihe Xu



Self-introduction

Dr. Qihe Xu, MD and PhD, Senior Lecturer in Renal Medicine & Integrative Chinese Medicine, Director of the King's Centre for Integrative Chinese Medicine (CICM) initiative, and Organiser of MSc Pharmacology Projects at King's College London (KCL).

After a decade of medical practice in Beijing, I started an academic career in London in 1999. I used to be Secretary-General, Chinese Students & Scholars Association in the UK, and President, Chinese Life Scientists Society in the UK.

In 2009-2012, I was the PI of the FP7 GP-TCM Project, which founded the GP-TCM RA. As a GP-TCM RA Life Member, I have served on the BoD for three terms. I was Vice-President (2012-2014), Newsletter Editor-in-chief (2017-2019), and am Newsletter Consulting Editor and Associate Editor-in-chief, WJTCM, official journal of the Association.

I am passionate about integrating TCM wisdom into tomorrow's medicine and pharmacology and my research focuses on TCM-inspired studies of kidney health and disease, herbal antifibrotics and botanical nephrotoxicity. Lately, I'm honoured to be nominated for the 2020 Qihuang International Prize, China Association of Chinese Medicine.

Personal statement: Why do you apply for the position? What will you do if elected?

The COVID-19 pandemic has brought grave challenges to us all. I put myself forward at such difficult times to show my continued support to the GP-TCM RA.

In the past years, I have particularly devoted myself to two things: (i) Through the GP-TCM RA Newsletters, disseminating the GP-TCM RA 3I principles (integrity, integration and innovation; *BMC Complement Altern Med.* 2013;13:132), GP-TCM consensuses (*J Ethnopharmacol.* 2012;140:458) and latest developments in TCM, science and EU-China cooperation; and (ii) Developing King's CICM, a KCL initiative since 2013.

My research and teaching at KCL have benefited from the GP-TCM 3I principles and consensuses on good practices, opportunities, challenges and priorities. Great progress has been made in TCM-inspired innovations, particularly in understanding novel mechanisms of TCM antifibrotics and new insights into kidney health, disease and care.

If elected, I will continue to promote the GP-TCM 3I principles and other GP-TCM



consensuses. I will strive for enhanced capability of the Association to serve members and to facilitate the work of Interest Groups and to promote collaboration.

Despite COVID-19 and Brexit, my belief in the value and power of good practice, integrative Chinese medicine and European-Chinese collaboration stays.

-- End --